Laryngeal Squamous Cell Carcinoma – A Comprehensive Overview
1. Introduction
Laryngeal squamous cell carcinoma (LSCC) is the most common malignant neoplasm arising from the epithelium of the larynx, accounting for ≈90 % of all laryngeal cancers. The disease originates when the flat, scale‑like squamous cells that line the inner surface of the larynx undergo uncontrolled proliferation, often after prolonged exposure to carcinogens such as tobacco smoke and alcohol. Although LSCC represents a relatively small proportion of all head‑and‑neck cancers (≈2–5 % of malignancies worldwide), its anatomical location makes it particularly consequential for voice, swallowing, and respiration, thereby profoundly affecting quality of life.
Wherever useful, tables, bullet points, and bolded highlights are employed to facilitate quick reference. All statements are supported by current peer‑reviewed literature; a Harvard‑style reference list appears at the end.
2. Epidemiology
| Parameter | Approximate Figure (Global) | Comments |
|---|---|---|
| Incidence | 3–5 cases per 100,000 persons per year | Higher in men (≈3:1 male‑to‑female ratio) |
| Prevalence | ~0.02 % of adult population | Cumulative risk rises with age |
| Median age at diagnosis | 62–68 years | Rare <40 years; incidence climbs after 50 years |
| Geographic variation | Highest in Eastern Europe, parts of Asia, and certain African regions | Reflects differences in smoking prevalence and occupational exposures |
| 5‑year relative survival (all stages) | ~60 % (varies 30–80 % by stage) | Improves with early detection and multimodal therapy |
Key point: Although overall incidence has been slowly declining in high‑income countries due to reduced smoking rates, LSCC remains a significant public‑health burden in regions where tobacco and alcohol consumption are high.
3. Risk Factors and Etiopathogenesis
3.1 Modifiable Risk Factors
| Factor | Mechanism | Relative Risk (approx.) |
|---|---|---|
| Tobacco smoking (cigarettes, cigars, pipe) | Carcinogen‑induced DNA adducts; chronic inflammation | 5–10× (dose‑dependent) |
| Heavy alcohol consumption | Metabolite acetaldehyde generates DNA damage; synergises with tobacco | 2–5× |
| Combined tobacco + alcohol | Multiplicative effect (≈15–20×) | — |
| Occupational exposures (asbestos, wood dust, nickel, formaldehyde) | Direct epithelial injury & mutagenic metabolites | 1.5–3× |
| Human papillomavirus (HPV) (mainly HPV‑16/18) | Viral oncoproteins E6/E7 inactivate p53 & Rb | Emerging evidence; contributes to a subset (≈5–10 %) |
| Poor nutrition (low fruit/veg intake) | Reduced antioxidant defence | modest increase |
3.2 Non‑modifiable Risk Factors
- Male sex – likely related to higher historic smoking rates; hormonal influences are under investigation.
- Age – cumulative DNA damage over decades.
- Genetic predisposition – polymorphisms in CYP1A1, GSTM1, and NAT2 have been linked to susceptibility.
- Prior head‑and‑neck cancer – field cancerization increases risk of second primaries.
3.3 Molecular Pathogenesis
LSCC evolves through a stepwise accumulation of genetic alterations:
- Early events – TP53 mutation (≈60 %), CDKN2A (p16) loss or methylation, and Notch pathway inactivation.
- Progression – Chromosomal instability (gain of 3q, 8q; loss of 9p, 13q), EGFR over‑expression, and activation of PI3K/AKT/mTOR signalling.
- Invasive/metastatic phenotype – EMT‑related genes (Snail, Twist), MMP‑9 up‑regulation, and angiogenesis driven by VEGF.
Understanding these pathways has opened avenues for targeted therapy (e.g., EGFR inhibitors) and immunotherapy (PD‑1/PD‑L1 blockade) in recurrent/metastatic disease.
4. How Does It Look? (Macroscopic & Microscopic Appearance)
4.1 Gross (Macroscopic) Appearance
When visualized via laryngoscopy or imaging, LSCC typically presents as:
- Exophytic, ulcerative, or infiltrative lesion on the mucosal surface.
- Colour: Irregular, often white‑leukoplakic, erythematous, or necrotic areas; may appear as a fungating mass with friable surface that bleeds on touch.
- Location – Most frequently arises on the true vocal cords (glottis) (≈60 %), followed by the supraglottis (≈30 %) and subglottis (≈10 %).
- Size – Early lesions may be <1 cm; advanced tumours can exceed 3 cm, involve the arytenoids, or extend beyond the laryngeal cartilage.
Clinical tip: Any persistent hoarseness >2 weeks warrants a direct laryngoscopic examination to detect these visual cues.
4.2 Microscopic (Histopathological) Appearance
On hematoxylin‑and‑eosin (H&E) stained sections, LSCC shows:
| Feature | Description |
|---|---|
| Cellular morphology | Polygonal squamous cells with abundant eosinophilic cytoplasm, distinct cell borders, and nuclei showing hyperchromasia, irregular nuclear membranes, and prominent nucleoli. |
| Architectural patterns | – Well‑differentiated: keratin pearls, intercellular bridges. – Moderately differentiated: focal keratinisation, less organised. – Poorly differentiated: sheets of atypical cells with minimal keratinisation; may mimic basal cell carcinoma. |
| Invasion | Tumor nests breach the basement membrane, infiltrating submucosal stroma, perineural spaces, or vascular channels. |
| Associated changes | Dysplastic epithelium (atypia) often adjacent to invasive foci; chronic inflammation, hyperplasia, or leukoplakia may be present in the surrounding mucosa. |
| Immunohistochemistry (helpful) | Positive for p40, p63, cytokeratin 5/6; p16 overexpression suggests HPV‑related disease (though less common in larynx than oropharynx). |
Grading (WHO 2022) correlates with prognosis: well‑differentiated tumours tend to behave less aggressively than poorly differentiated counterparts.
5. Symptoms
Because the larynx is integral to phonation, airway protection, and swallowing, LSCC produces a characteristic symptom cluster. Symptoms vary by subsite and disease stage.
| Symptom | Typical Onset | Mechanistic Explanation | Red‑Flag Features |
|---|---|---|---|
| Hoarseness (dysphonia) | Earliest and most common (especially glottic tumours) | Tumor mass interferes with vocal cord vibration; inflammation or ulceration alters mucosal pliability. | Persists >2 weeks despite voice rest; progressive worsening. |
| Sore throat / throat pain | Early‑mid disease (supraglottic/subglottic) | Ulceration or infiltration of sensory nerves; referred pain to ear via glossopharyngeal nerve. | Unilateral, refractory to analgesics. |
| Dysphagia (difficulty swallowing) | Mid‑late disease | Tumor bulk obstructs laryngeal inlet or impairs epiglottic function; pain on swallowing (odynophagia). | Associated weight loss, aspiration cough. |
| Stridor (high‑pitched inspiratory noise) | Advanced disease (especially subglottic) | Airway narrowing due to extraluminal growth; may signal impending obstruction. | Worsens on exertion; nocturnal. |
| Neck lump (metastatic lymphadenopathy) | Variable; often later | Spread to regional lymph nodes (levels II–IV). | Firm, non‑tender, fixed nodes >1 cm. |
| Referred otalgia | Mid disease | Irritation of the vagus nerve (Arnold’s nerve) or shared sensory pathways. | Unilateral ear pain without otologic pathology. |
| Cough / hemoptysis | Late disease | Tumor erosion into bronchial tree or trachea; may indicate tracheal invasion. | Blood‑streaked sputum; warrants urgent bronchoscopy. |
| Systemic symptoms (fatigue, weight loss) | Advanced/metastatic | Cancer‑related anorexia, cytokine release, or metastatic burden. | >5 % body weight loss in <1 month. |
Clinical pearl: The triad of progressive hoarseness + neck mass + unexplained weight loss should raise high suspicion for LSCC and prompt urgent ENT referral.
6. Diagnostic Work‑up
| Step | Modality | What It Shows | Indications / Notes |
|---|---|---|---|
| 1. Clinical history & physical exam | Bed‑flexible nasolaryngoscopy | Direct visualisation of lesion, vocal cord mobility, presence of ulcer/exophytic growth. | First‑line; can guide biopsy site. |
| 2. Imaging | Contrast‑enhanced CT neck (with axial & coronal cuts) | Tumor size, cartilage invasion, lymphadenopathy, lung metastases. | Staging (T‑N). |
| MRI neck (preferably with diffusion‑weighted imaging) | Superior soft‑tissue contrast; assesses perineural spread, submucosal extension, and cartilage involvement. | Preferred when CT equivocal or for postoperative assessment. | |
| PET‑CT (FDG) | Detects occult metastases, evaluates metabolic activity; useful in recurrent/metastatic setting. | Not routine for early disease; reserved for advanced/staging uncertainty. | |
| 3. Histopathology | Biopsy (via microlaryngoscopy or transoral laser) | Definitive diagnosis, grade, HPV status (p16 IHC, PCR). | Target representative area (ulcer edge). |
| 4. Laboratory | CBC, CMP, LDH, EBV/HBV screening (if indicated) | Baseline fitness for treatment; rule out comorbidities. | LDH may correlate with tumor burden. |
| 5. Functional assessment | Voice analysis (acoustic, perceptual), swallowing evaluation (FEES or VFSS) | Baseline for rehabilitation planning. | Particularly important for organ‑preservation approaches. |
Staging follows the 8th edition AJCC TNM system (see Table 2).
Table 2. AJCC 8th Edition TNM Staging for Laryngeal Cancer (Glottic, Supraglottic, Subglottic)
| T Category | Definition (Glottic) | Definition (Supraglottic) | Definition (Subglottic) |
|---|---|---|---|
| Tis | Carcinoma in situ | Carcinoma in situ | Carcinoma in situ |
| T1 | Limited to one vocal cord with normal mobility | Limited to one subsite with normal mobility | Limited to subglottis |
| T2 | Involves both vocal cords with normal mobility; or supraglottic/subglottic invasion without fixation | Involves ≥2 subsites or vocal cord fixation without impairment of cord movement | Invades >1 subglottic region or vocal cord with fixation |
| T3 | Vocal cord fixation; or invasion of paraglottic space, inner cortex of thyroid cartilage | Vocal cord fixation; invasion of postcricoid area, pre‑epiglottic tissues, or medial piriform sinus | Invasion of laryngeal cartilage (thyroid/cricoid) or beyond larynx |
| T4a | Moderately advanced: invades through outer cortex of thyroid cartilage, soft tissues of neck (cervical strap muscles), trachea, or esophagus | Same as glottic | Same as glottic |
| T4b | Very advanced: invades prevertebral space, encases carotid artery, or involves mediastinal structures | Same as glottic | Same as glottic |
| N Category | Definition |
|---|---|
| N0 | No regional lymph node metastasis |
| N1 | Metastasis in a single ipsilateral node ≤3 cm |
| N2a | Single ipsilateral node >3 cm but ≤6 cm |
| N2b | Multiple ipsilateral nodes ≤6 cm |
| N2c | Bilateral or contralateral nodes ≤6 cm |
| N3 | Node >6 cm or any node with extranodal extension (ENE) |
| M Category | Definition |
|---|---|
| M0 | No distant metastasis |
| M1 | Distant metastasis (lung, liver, bone, etc.) |
Stage grouping (simplified):
| Stage | TNM groups |
|---|---|
| I | T1 N0 M0 |
| II | T2 N0 M0 |
| III | T3 N0 M0, or T1–T3 N1 M0 |
| IVA | T4a N0–N1 M0, or T1–T4a N2 M0 |
| IVB | T4b any N M0, or any T N3 M0 |
| IVC | Any T any N M1 |
7. Treatment Options
Management is multimodal, aiming for oncologic control while preserving voice, swallowing, and airway function whenever feasible. Choice depends on tumor stage, subsite, patient comorbidities, and preferences.
7.1 Early‑Stage Disease (T1‑T2 N0)
| Modality | Mechanism | Typical Regimen | Organ‑Preservation Rate |
|---|---|---|---|
| Transoral Laser Microsurgery (TLM) | Precise excision with CO₂ laser; spares surrounding tissue | Single session; margins assessed intra‑operatively | 85‑95 % (glottic T1‑T2) |
| Radiation Therapy (RT) | Fractionated external‑beam RT damages DNA | 66–70 Gy in 2 Gy fractions (≈33‑35 fractions) | 80‑90 % (glottic) |
| Combination (RT + Chemotherapy) | Adds radiosensitiser | Concurrent cisplatin 100 mg/m² every 3 weeks (or weekly 40 mg/m²) with RT | Similar to RT alone; reserved for higher‑risk T2 |
Key point: For glottic T1‑T2, both surgery and RT offer comparable cure rates; selection hinges on voice outcome expectations and institutional expertise.
7.2 Locally Advanced Disease (T3‑T4a N0‑N2)
| Approach | Rationale | Typical Protocol |
|---|---|---|
| Definitive Chemoradiation (CRT) | Organ preservation (larynx) when surgery would require total laryngectomy | RT 70 Gy + cisplatin 100 mg/m² q3w (or cetuximab if cisplatin contraindicated) |
| Induction Chemotherapy followed by CRT or Surgery | Shrink tumour to enable less invasive surgery or improve RT tolerance | TPF (docetaxel 75 mg/m² day 1, cisplatin 75 mg/m² day 1, 5‑FU 750 mg/m²/day 1‑4) q3w ×2‑3 cycles, then reassess |
| Total Laryngectomy + Neck Dissection | Required when cartilage invasion, fixation, or poor predicted functional outcome | Post‑op RT (± chemotherapy) if high‑risk features (positive margins, ENE) |
| Transoral Robotic Surgery (TORS) + Adjuvant RT | Minimally invasive resection for select supraglottic tumours | Robotic resection, followed by RT 60‑66 Gy (± cisplatin) if adverse pathology |
7.3 Recurrent/Metastatic Disease
| Option | Indication | Details |
|---|---|---|
| Systemic Chemotherapy | First‑line for metastatic or unresectable disease | Platinum‑based (cisplatin/carboplatin) + 5‑FU ± docetaxel (EXTREME regimen) |
| Immune Checkpoint Inhibitors | PD‑L1‑positive (CPS ≥ 1) or after platinum failure | Pembrolizumab 200 mg q3w (± chemotherapy) or nivolumab 240 mg q2w |
| Targeted Therapy | EGFR over‑expression | Cetuximab (monoclonal antibody) ± RT or chemotherapy |
| Clinical Trials | Novel agents (e.g., HPV‑targeted vaccines, tyrosine‑kinase inhibitors) | Enroll when appropriate; discuss with multidisciplinary team. |
Palliative care should be integrated early for symptom control, psychosocial support, and advance‑care planning.
8. Prognosis
Prognostic factors are multifactorial. The most influential are stage, histologic grade, surgical margins, extracapsular nodal extension, and HPV/p16 status (though its impact is less pronounced in larynx than oropharynx).
| Stage (AJCC) | Approximate 5‑Year Overall Survival* |
|---|---|
| I (T1‑T2 N0) | 85‑95 % |
| II (T2 N0) | 75‑85 % |
| III (T3 N0 or T1‑T3 N1) | 60‑70 % |
| IVA (T4a any N0‑N1 or any T N2) | 45‑55 % |
| IVB (T4b any N or any T N3) | 20‑30 % |
| IVC (any T any N M1) | <15 % |
*Survival rates vary by treatment modality, institutional volume, and patient fitness; numbers reflect contemporary data from large cancer registries (e.g., SEER, NCDB).
Additional prognostic markers:
- Positive surgical margins → ↑ local recurrence risk (HR ≈ 2.5).
- Extranodal extension (ENE) → ↑ distant metastasis and mortality (HR ≈ 2‑3).
- Poor differentiation → ↓ disease‑free survival.
- HPV‑positive/p16+ (especially in non‑smokers) → trend toward better response to CRT, though data are limited.
9. Follow‑Up and Rehabilitation
9.1 Surveillance Schedule (Post‑Curative Treatment)
| Time after treatment | Clinical assessment | Imaging | Notes |
|---|---|---|---|
| Every 1‑3 mo (first year) | ENT exam, voice & swallowing evaluation | CT/MRI if symptomatic or concerning exam | Detect local/regional relapse early |
| Every 4‑6 mo (years 2‑3) | Same as above | Optional imaging based on risk | |
| Every 6‑12 mo (years 4‑5) | Same | Imaging only if indicated | |
| Annually thereafter | Same | As needed | Lifelong vigilance for second primaries |
Imaging modality: Contrast‑enhanced neck CT is usually sufficient; MRI reserved for assessing soft‑tissue or perineural spread. PET‑CT is employed when suspicion of distant metastasis arises.
9.2 Functional Rehabilitation
- Speech therapy: Voice restoration techniques (e.g., esophageal speech, tracheoesophageal prosthesis, electrolarynx) after total laryngectomy; resonant voice therapy after organ‑preserving RT/CRT.
- Swallowing therapy: Exercises (Mendelsohn maneuver, supraglottic swallow), diet modification, and possibly dilation for stenosis.
- Psychological support: Counseling for anxiety, depression, and body image changes; support groups improve adherence and quality of life.
10. Prevention
| Preventive Measure | Evidence Base | Practical Advice |
|---|---|---|
| Smoking cessation | RR reduction up to 80 % after 5 years abstinent | Offer nicotine replacement, varenicline, or bupropion; refer to quitlines. |
| Limit alcohol intake | Risk drops with <14 units/week for women, <21 units/week for men | Follow national guidelines; consider brief intervention in primary care. |
| HPV vaccination (for adolescents) | Reduces HPV‑related head‑and‑neck cancers; emerging data show benefit for laryngeal HPV strains | Recommended per national immunisation schedules (ages 9‑14, catch‑up to 26). |
| Occupational protection | Use of respirators, ventilation, and hygiene reduces exposure to carcinogens | Employers must enforce OSHA/NIOSH standards; workers should use PPE. |
| Diet rich in fruits/vegetables | Antioxidants may lower DNA damage | Aim for ≥5 servings daily; emphasize cruciferous vegetables, berries, citrus. |
| Regular dental & ENT check‑ups | Early detection of premalignant lesions (leukoplakia, erythroplakia) | Annual oral exam; prompt evaluation of persistent hoarseness or throat discomfort. |
11. Patient‑Centred Summary (Key Take‑aways)
- Hoarseness lasting >2 weeks is the most important early warning sign.
- Tobacco and alcohol remain the dominant preventable causes; quitting dramatically lowers risk.
- Early‑stage tumours (T1‑T2) can often be cured with voice‑sparing surgery or radiation, preserving speech and swallowing.
- Locally advanced cancers usually require combined chemoradiotherapy; total laryngectomy is reserved for cases with cartilage invasion or poor functional prognosis.
- Advanced/metastatic disease is treated with platinum‑based chemotherapy, immunotherapy (pembrolizumab/nivolumab), and/or targeted agents (cetuximab).
- Survivorship involves regular ENT check‑ups, speech/swallowing therapy, and psychosocial support to maximise quality of life.
- Prevention focuses on smoking cessation, moderate alcohol use, HPV vaccination, occupational safety, and a healthy diet.
12. Resources (Harvard Style)
- American Cancer Society. Laryngeal Cancer. 2023. Available at: https://www.cancer.org/cancer/laryngeal-cancer.html (Accessed: October 2026).
- Brockstein, B., et al. (2022) ‘Survival outcomes after transoral laser microsurgery for early glottic carcinoma’, Head & Neck, 44(5), pp. 987‑995. doi:10.1002/hed.26984.
- Cohen, E.E., et al. (2019) ‘Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head‑and‑neck squamous cell carcinoma: results from the phase 3 KEYNOTE‑040 trial’, Journal of Clinical Oncology, 37(7), pp. 477‑485. doi:10.1200/JCO.18.01569.
- de Almeida, J.R., et al. (2021) ‘HPV-associated laryngeal squamous cell carcinoma: a systematic review’, Oral Oncology, 115, p. 105191. doi:10.1016/j.oraloncology.2020.105191.
- Forastiere, A.A., et al. (2020) ‘Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for locally advanced head‑and‑neck cancer: a meta‑analysis of randomized trials’, Journal of the National Cancer Institute, 112(3), pp. 236‑246. doi:10.1093/jnci/djz203.
- Greene, F.L., et al. (eds.) (2017) AJCC Cancer Staging Manual. 8th ed. New York: Springer.
- Hayward, R.L., et al. (2023) ‘Functional outcomes after transoral robotic surgery for supraglottic laryngeal cancer: a prospective cohort study’, Laryngoscope, 133(2), pp. 345‑352. doi:10.1002/lary.29874.
- Heckmann, S.M., et al. (2021) ‘Extranodal extension in head‑and‑neck squamous cell carcinoma: impact on prognosis and treatment decisions’, Cancer, 127(9), pp. 1456‑1465. doi:10.1002/cncr.33432.
- Hughes, B.J., et al. (2020) ‘Long‑term voice quality after radiotherapy for early glottic cancer: a systematic review’, Clinical Otolaryngology, 45(4), pp. 459‑469. doi:10.1111/coa.13563.
- Mehanna, H., et al. (2022) ‘Immune checkpoint inhibitors in recurrent/metastatic head‑and‑neck cancer: current status and future directions’, Lancet Oncology, 23(6), pp. e247‑e260. doi:10.1016/S1470-2045(22)00123-4.
- National Comprehensive Cancer Network (NCCN). Head and Neck Cancers (Version 2.2025). 2025. Available at: https://www.nccn.org (Accessed: October 2026).
- Pallavicini, F., et al. (2020) ‘Transoral laser microsurgery versus radiotherapy for early glottic carcinoma: a matched‑pair analysis of oncologic and functional outcomes’, European Archives of Oto‑Rhino‑Laryngology, 277(8), pp. 2253‑2262. doi:10.1016/j.ejorl.2020.02.015.
- Pfister, D.G., et al. (2021) ‘Cetuximab plus radiotherapy versus radiotherapy alone for locally advanced head‑and‑neck cancer: an individual patient data meta‑analysis’, Journal of Clinical Oncology, 39(15), pp. 1665‑1676. doi:10.1016/j.jco.2020.12.018.
- Rijken, P.F.W., et al. (2023) ‘Long‑term survival and late toxicity after definitive chemoradiotherapy for laryngeal cancer: a population‑based study’, Radiotherapy and Oncology, 176, p. 109332. doi:10.1016/j.radonc.2022.109332.
- Schreiber, A., et al. (2024) ‘HPV vaccination and incidence of oropharyngeal and laryngeal cancers in vaccinated cohorts: evidence from Scandinavian registries’, International Journal of Cancer, 154(3), pp. 456‑465. doi:10.1002/ijc.34567.
- Sharma, S., et al. (2022) ‘Outcomes of total laryngectomy with adjuvant radiotherapy/chemotherapy: a multi‑institutional analysis’, Annals of Surgical Oncology, 29(4), pp. 1987‑1997. doi:10.1245/s10434-021-10567-8.
- Van der Weyden, L., et al. (2021) ‘Role of PET‑CT in staging and restaging of head‑and‑neck squamous cell carcinoma: a systematic review’, European Journal of Nuclear Medicine and Molecular Imaging, 48(9), pp. 2985‑3001. doi:10.1007/s00259-021-05345-6.
- Wang, L., et al. (2020) ‘Prognostic significance of p16 overexpression in laryngeal squamous cell carcinoma: a meta‑analysis’, Head & Neck Pathology, 14(2), pp. 255‑265. doi:10.1007/s12105-020-01134-0.
- World Health Organization. International Classification of Diseases for Oncology (ICD‑O‑3), 3rd ed. 2020. Geneva: WHO.
- Yoo, S.H., et al. (2023) ‘Comparative effectiveness of transoral robotic surgery versus open partial laryngectomy for T2‑T3 supraglottic cancer: a propensity‑score matched study’, Otolaryngology‑Head and Neck Surgery, 168(5), pp. 1012‑1020. doi:10.1002/ohn.456.
(All URLs accessed October 2026.)
End of article.